--- title: "U.S. stock market midday update: Nexgel up 18.66%! Medical innovation + influx of funds, short-term increase exceeds 50%" type: "News" locale: "en" url: "https://longbridge.com/en/news/295951931.md" description: "Nexgel rose 18.66%; Aiqi Technology rose 3.20%, with a transaction volume of USD 550,500; Alcon rose 1.35%, with a transaction volume of USD 210,100; Medline rose 0.39%, with a transaction volume of USD 209,900; Solventum rose 1.90%, with a market value of USD 15 billion" datetime: "2026-08-14T15:08:08.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/295951931.md) - [en](https://longbridge.com/en/news/295951931.md) - [zh-HK](https://longbridge.com/zh-HK/news/295951931.md) generator: "portal-rs" --- # U.S. stock market midday update: Nexgel up 18.66%! Medical innovation + influx of funds, short-term increase exceeds 50% **U.S. Stock Market Midday Update** Nexgel rose by 18.66%. Based on recent key news: 1. On August 11, Nexgel's stock price increased by 52.61% over the past five days, primarily driven by positive market reactions to its innovative products. Nexgel's innovative technology in the medical field has attracted investor attention, leading to a significant rise in stock price. 2. Recently, interest in medical technology companies has increased in the market, driving up Nexgel's stock price. Investors are optimistic about the company's potential in the medical technology sector, further propelling the stock price upward. 3. Analysts hold a positive outlook on Nexgel's future growth prospects, believing that its innovations in medical technology will continue to drive stock price increases. Analysts' optimistic forecasts have bolstered market confidence, contributing to the rise in stock price. The medical technology industry has performed strongly recently, with significant capital inflows. **Stocks with High Trading Volume in the Industry** Angelalign rose by 3.20%. Based on recent key news: 1. On August 12, the Jinan Intermediate People's Court made a favorable ruling in the patent infringement case against Angelalign, determining that Angelalign's Chinese subsidiary infringed on Angelalign's patents and ordered the cessation of the use, production, and sale of related technologies. This ruling solidifies Angelalign's position in intellectual property protection and drives up the stock price. 2. On August 12, Angelalign announced it received $1.48 million in compensation, further strengthening its commitment to global innovation protection. This news has boosted investor confidence and promoted the rise in stock price. 3. On August 12, Angelalign obtained an injunction in Europe and is pursuing five patent claims with the U.S. International Trade Commission, with a preliminary ruling expected in November 2026. These legal actions demonstrate the company's proactive stance in protecting its rights globally, uplifting market sentiment. Industry patent disputes are intensifying, leading to noticeable market volatility. Alcon rose by 1.35%, with increased trading volume. Based on recent key news: 1. On August 11, Alcon raised its core diluted earnings per share growth forecast for 2026 to 12%-15% and increased its core operating margin forecast by 90-190 basis points, driving up the stock price. Source: Zhitong Finance 2. On August 11, Alcon's net sales for the second quarter increased by 8% year-on-year, reaching $2.78 billion, exceeding analysts' expectations and further boosting market confidence. Source: Wall Street Insights 3. On August 11, analysts pointed out that Alcon's collaboration with RxSight will improve profit margins, enhance strategic direction, and support stock price increases. Source: Jinshi Data The ophthalmic industry is experiencing strong growth, with a stable macroeconomic environment. Medline rose by 0.39%. Based on recent key news: 1. On August 12, Medline signed a supply agreement with Caremax, under which Caremax will procure Medline-branded incontinence products and ship them to patients' homes through Medline's Home Direct program The plan offers next-day delivery service, covering 95% of customers in the United States. This move enhances Medline's market coverage and drives up the stock price. 2. On August 12, Medline completed the implementation of the Prime Vendor agreement with Doctors Outpatient Surgery Center. This agreement allows the center to access Medline's medical surgical product portfolio and simplifies the ordering and delivery process through distribution and supply chain services. Cost savings were the main driver for the center's decision to switch suppliers, boosting market confidence in Medline. 3. On August 11, GIC Private sold 590,284 shares of Medline Class A common stock, reducing its direct holdings to 24,402,482 shares. Nevertheless, Hux Investment still holds 91,555,447 shares of Class A common stock. This transaction attracted market attention but did not have a significant negative impact on the stock price. The overall performance of the healthcare industry remains stable, with noticeable capital inflows. **Stocks Ranked Among the Top by Market Capitalization in the Industry** Solventum rose by 1.90%. Based on recent key news: 1. On August 11, Curreen Capital sold its holdings in Solventum in the second quarter. The fund performed well in the second quarter, exceeding the returns of the S&P 500 and MSCI World Index, but chose to sell Solventum, which may lead to a decline in market confidence in the stock and affect its price. 2. On August 11, Solventum released its latest corporate announcement, emphasizing its performance in the market and future plans. Although the announcement did not disclose detailed content, the market's optimistic expectations for the company's future may drive the stock price up. 3. No other significant news recently. Capital flows indicate active trading, and industry trends should be monitored ### Related Stocks - [NXGL.US](https://longbridge.com/en/quote/NXGL.US.md) - [ALGN.US](https://longbridge.com/en/quote/ALGN.US.md) - [ALC.US](https://longbridge.com/en/quote/ALC.US.md) - [MDLN.US](https://longbridge.com/en/quote/MDLN.US.md) - [SOLV.US](https://longbridge.com/en/quote/SOLV.US.md) ## Related News & Research - [NXGL: Q2 revenue reached $3.69M with a $2.87M net loss; integration and expansion efforts continue](https://longbridge.com/en/news/296106108.md) - [Nexgel’s Celularity Deal: Execution, Integration, and Profitability Risks from $13.3 Million Biomaterials Acquisition](https://longbridge.com/en/news/296183101.md) - [Promise Analyzes Telehealth Licensing Rules as Compact Hits Record 3,633 Licenses in a Month](https://longbridge.com/en/news/296635882.md) - [Medline tallies tariff refunds as Q2 sales rise 11.6%](https://longbridge.com/en/news/296260871.md) - [19:54 ETMDLN Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages Medline Inc. (NASDAQ: MDLN) Investors to Contact the Firm](https://longbridge.com/en/news/296279958.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**